This article first appeared on GuruFocus .
Release Date: November 12, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
PI Industries Ltd ( BOM:523642 ) reported a 50% year-on-year growth in its pharma business, driven by new customer acquisitions and pipeline development.
-
The company has commercialized 5 new molecules in the first half of the fiscal year and plans to commercialize 8 to 10 new molecules in the coming fiscal year.
-
New products in the chemical exports segment have seen a 38% year-on-year growth, demonstrating the success of the company's de-risking strategy.
-
PI Industries Ltd ( BOM:523642 ) is investing in the biologicals segment, with a new research center in Hyderabad and plans to expand its market presence in the US, Brazil, Europe, Mexico, and India.
-
The company maintains a strong focus on financial discipline, aiming for sustainable growth with robust cash flows and a healthy return on capital.
Negative Points
-
PI Industries Ltd ( BOM:523642 ) experienced a 16% decline in revenue for Q2 compared to the same period last year, primarily due to adverse weather conditions and regulatory challenges.
-
The domestic business saw a 5% year-on-year decline in H1, impacted by erratic rainfall and abrupt regulatory actions affecting demand.
-
The global crop protection industry is facing a prolonged down cycle, with low commodity prices, rising interest rates, and inventory destocking affecting performance.
-
The company's biological business has been impacted by regulatory changes, leading to significant disruptions in sales.
-
PI Industries Ltd ( BOM:523642 ) is currently in an investment phase for its pharma and biological segments, resulting in higher overheads and delayed profitability.
Q & A Highlights
-
Warning! GuruFocus has detected 2 Warning Sign with BOM:523642.
-
Is BOM:523642 fairly valued? Test your thesis with our free DCF calculator.
Q: Given the sharp decline in the first half, what growth do you expect in exports, domestic, and pharma businesses for the remainder of the year? A: (Executive Vice Chairman and Managing Director) We anticipate a positive trajectory in the domestic and export agri-businesses, particularly from the rabi season, due to favorable water levels. However, this is contingent on climate conditions. We expect the export side to see improvements in Q4, driven by restocking in the US and other markets.
Q: With competitors exiting the Indian market, are there opportunities for PI Industries to gain market share? A: (Executive Vice Chairman and Managing Director) While we are open to opportunities, we cannot comment specifically on competitors' business decisions. However, any exit could potentially create market share opportunities for us.
Q: Can you explain the significant increase in contract assets on the balance sheet? A: (Group Chief Financial Officer) The increase in contract assets aligns with customer delivery schedules for H2. These represent finished goods produced for confirmed customer orders, which will be delivered over the next 1 to 2 quarters.
Q: What is the outlook for the pharma business, considering the biotech funding slowdown? A: (Group Chief Financial Officer) Despite headwinds, the pharma business is performing well, with a positive long-term outlook. We have onboarded new customers and expect to maintain growth, although the 75% growth target may be challenging.
Q: How is the biological business expected to scale up, and when will it become profitable? A: (Global CEO Biologicals) We are in the investment phase, focusing on market and product development. Significant growth is expected in the coming years, but profitability will follow once we achieve scale.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
